OptiScan Imaging Limited (ASX: OIL) (‘the Company’ or ‘OptiScan’) is pleased to advise that its Eastern China distributor has been successful in two tenders for the sale of the FIVE2 (ViewnVivo) system. Formal orders are expected to be received next month with revenues in excess of A$350k to be received from the 2 sales. Success in these tenders brings sales to 3 since Optiscan changed its distribution arrangements in China late last year.
Executive Chairman and CEO of OptiScan, Darren Lurie, said “Since being implemented late last year, we are delighted to see the progress that our multi-distributor model for the Chinese market is making. In addition to these sales, our distributors are actively working to develop their pipeline of further sales notwithstanding the disruption caused by COVID-19 with further initiatives including webinars planned.”
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early-stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.